Trial Profile

A proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2025 According to Sol-Gel media release, SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial
15 Nov 2024 According to Sol-Gel media release, proof-of-concept study for SGT-210 (topical erlotinib) in Darier disease patients, targeting a market of between $200 million to $300 million.
15 Nov 2024 Status changed from not yet recruiting to recruiting, according to Sol-Gel media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com